Supplemental Evidence and Data Request on Healthcare Delivery of Clinical Preventive Services for People With Disabilities, 74996-74998 [2023-24057]
Download as PDF
<![CDATA[
74996
Federal Register / Vol. 88, No. 210 / Wednesday, November 1, 2023 / Notices
pertaining to conditions in the ocean
freight delivery system to the
Commission. Specifically, the
Committee advises the Federal Maritime
Commission on policies relating to the
competitiveness, reliability, integrity,
and fairness of the international ocean
freight delivery system. 46 U.S.C.
42502(b).
The Committee will receive an update
from each of its subcommittees. The
Committee may receive proposals for
recommendations to the Federal
Maritime Commission and may vote on
these recommendations. Any proposed
recommendations will be available for
the public to view in advance of the
meeting on the NSAC’s website, https://
www.fmc.gov/industry-oversight/
national-shipper-advisory-committee/.
Public Comments: Members of the
public may submit written comments to
NSAC at any time. Comments should be
addressed to NSAC, c/o Dylan
Richmond, Federal Maritime
Commission, 800 North Capitol St. NW,
Washington, DC 20573 or nsac@
fmc.gov.
The Committee will also take public
comment at its meeting. If attending the
meeting in person and providing
comments, please note that in the
registration request. Comments are most
helpful if they address the Committee’s
objectives or their proposed
recommendations. Comments at the
meeting will be limited to 3 minutes
each.
A copy of all meeting documentation,
including meeting minutes, will be
available at www.fmc.gov following the
meeting.
By the Commission.
Dated: October 27, 2023.
Carl Savoy,
Federal Register Alternate Liaison Officer.
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2023–24122 Filed 10–31–23; 8:45 am]
BILLING CODE P
[FR Doc. 2023–24072 Filed 10–31–23; 8:45 am]
BILLING CODE 6730–02–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
FEDERAL RESERVE SYSTEM
Agency for Healthcare Research and
Quality
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
ddrumheller on DSK120RN23PROD with NOTICES1
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in paragraph 7 of
the Act.
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington DC 20551–0001, not later
than November 16, 2023.
A. Federal Reserve Bank of Chicago
(Colette A. Fried, Assistant Vice
President) 230 South LaSalle Street,
Chicago, IL 60604) [Colette.A.Fried@
chi.frb.org]:
1. Andrew L. Prather and Tina
Prather, both of Petersburg, Illinois;
Elizabeth A. Prather, Virginia, Illinois;
and Laura J. Prather, individually and
as trustee of the Laura J. Prather Trust,
both of Creve Coeur, Missouri; to join
the Prather Family Control Group, a
group acting in concert, to retain voting
shares of Petefish, Skiles Bancshares,
Inc., and thereby indirectly retain voting
shares of Petefish, Skiles & Company,
both of Virginia, Illinois.
The notificants listed below have
applied under the Change in Bank
Control Act (Act) (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
applications are set forth in paragraph 7
of the Act (12 U.S.C. 1817(j)(7)).
The public portions of the
applications listed below, as well as
other related filings required by the
VerDate Sep<11>2014
19:48 Oct 31, 2023
Jkt 262001
Supplemental Evidence and Data
Request on Healthcare Delivery of
Clinical Preventive Services for People
With Disabilities
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Request for supplemental
evidence and data submission.
AGENCY:
The Agency for Healthcare
Research and Quality (AHRQ) is seeking
scientific information submissions from
the public. Scientific information is
being solicited to inform our review on
Healthcare Delivery of Clinical
SUMMARY:
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
Preventive Services for People with
Disabilities, which is currently being
conducted by the AHRQ’s Evidencebased Practice Centers (EPC) Program.
Access to published and unpublished
pertinent scientific information will
improve the quality of this review.
DATES: Submission Deadline on or
before December 1, 2023.
ADDRESSES:
Email submissions: epc@
ahrq.hhs.gov.
Print submissions:
Mailing Address: Center for Evidence
and Practice Improvement, Agency for
Healthcare Research and Quality,
ATTN: EPC SEADs Coordinator, 5600
Fishers Lane, Mail Stop 06E53A,
Rockville, MD 20857.
Shipping Address (FedEx, UPS, etc.):
Center for Evidence and Practice
Improvement, Agency for Healthcare
Research and Quality, ATTN: EPC
SEADs Coordinator, 5600 Fishers Lane,
Mail Stop 06E77D, Rockville, MD
20857.
FOR FURTHER INFORMATION CONTACT:
Kelly Carper, Telephone: 301–427–1656
or Email: epc@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION: The
Agency for Healthcare Research and
Quality has commissioned the
Evidence-based Practice Centers (EPC)
Program to complete a review of the
evidence for Healthcare Delivery of
Clinical Preventive Services for People
with Disabilities. AHRQ is conducting
this review pursuant to section 902 of
the Public Health Service Act, 42 U.S.C.
299a.
The EPC Program is dedicated to
identifying as many studies as possible
that are relevant to the questions for
each of its reviews. In order to do so, we
are supplementing the usual manual
and electronic database searches of the
literature by requesting information
from the public (e.g., details of studies
conducted). We are looking for studies
that report on Healthcare Delivery of
Clinical Preventive Services for People
with Disabilities. The entire research
protocol is available online at: https://
effectivehealthcare.ahrq.gov/products/
people-with-disabilities/protocol.
This is to notify the public that the
EPC Program would find the following
information on Healthcare Delivery of
Clinical Preventive Services for People
with Disabilities helpful:
D A list of completed studies that
your organization has sponsored for this
topic. In the list, please indicate
whether results are available on
ClinicalTrials.gov along with the
ClinicalTrials.gov trial number.
D For completed studies that do not
have results on ClinicalTrials.gov, a
E:\FR\FM\01NON1.SGM
01NON1
Federal Register / Vol. 88, No. 210 / Wednesday, November 1, 2023 / Notices
summary, including the following
elements, if relevant: study number,
study period, design, methodology,
indication and diagnosis, proper use
instructions, inclusion and exclusion
criteria, primary and secondary
outcomes, baseline characteristics,
number of patients screened/eligible/
enrolled/lost to follow-up/withdrawn/
analyzed, effectiveness/efficacy, and
safety results.
D A list of ongoing studies that your
organization has sponsored for this
topic. In the list, please provide the
ClinicalTrials.gov trial number or, if the
trial is not registered, the protocol for
the study including, if relevant, a study
number, the study period, design,
methodology, indication and diagnosis,
proper use instructions, inclusion and
exclusion criteria, and primary and
secondary outcomes.
D Description of whether the above
studies constitute ALL Phase II and
above clinical trials sponsored by your
organization for this topic and an index
outlining the relevant information in
each submitted file.
Your contribution is very beneficial to
the Program. Materials submitted must
be publicly available or able to be made
public. Materials that are considered
confidential; marketing materials; study
types not included in the review; or
information on topics not included in
the review cannot be used by the EPC
Program. This is a voluntary request for
information, and all costs for complying
with this request must be borne by the
submitter.
The draft of this review will be posted
on AHRQ’s EPC Program website and
available for public comment for a
period of 4 weeks. If you would like to
be notified when the draft is posted,
please sign up for the email list at:
https://www.effectivehealthcare.
ahrq.gov/email-updates.
The review will answer the following
questions. This information is provided
as background. AHRQ is not requesting
that the public provide answers to these
questions.
Key Questions
Key Question 1. What are the primary
barriers and facilitatorsa to the receipt of
clinical preventive services among
people with disabilities?
a. How do these barriers/facilitators
vary according to preventive service?
b. How do these barriers/facilitators
vary according to type and/or severity of
disability?
c. How do these barriers/facilitators
vary according to characteristics such
as: gender, race/ethnicity, economic
status, LGBTQ+ status, or geographic
location?
Key Question 2. What is the
effectiveness of interventions to
improve the receipt of clinical
preventive services among people with
disabilities?
a. How does the effectiveness vary
according to preventive service?
b. How does the effectiveness vary
according to type and/or severity of
disability?
c. How does the effectiveness vary
according to characteristics such as:
gender, race/ethnicity, economic status,
LGBTQ+ status, or geographic location?
Key Question 3. What are the
characteristics and/or components of
interventions that contribute to their
effectiveness (or lack of effectiveness) in
mitigating barriers to the receipt of
clinical preventive services among
people with disabilities?
74997
a. How does the effectiveness vary
according to preventive service?
b. How does the effectiveness vary
according to type and/or severity of
disability?
c. How does the effectiveness vary
according to characteristics such as:
gender, race/ethnicity, economic status,
LGBTQ+ status, or geographic location?
Key Question 4. What are the harms
of intervention programs to mitigate
barriers to the receipt of clinical
preventive services among people with
disabilities?
a. How do the harms vary according
to preventive service?
b. How do the harms vary according
to type and/or severity of disability?
c. How do the harms vary according
to characteristics such as: gender, race/
ethnicity, economic status, LGBTQ+
status, or geographic location?
a Categories of barriers and facilitators
may include but are not limited to:
• Environment-level (e.g.,
transportation; need/availability of
guardian or caregiver)
• Person-level (e.g., fear; discomfort;
functional ability; self-efficacy)
• Provider-level (e.g., disability
knowledge/assumptions; bias or
‘‘ableism’’; communication skills)
• Health system (e.g., insurance;
patient functionality information in
records; procedural accommodations,
such as visit length and clinician
reimbursement)
• Accessibility of health facilities
(e.g., physical facility; equipment;
sensory environment; telehealth)
• Accessible communication (e.g.,
within facility; from outside of facility)
• Policy-level (e.g., Federal or State
laws)
ddrumheller on DSK120RN23PROD with NOTICES1
PICOTS (POPULATIONS, INTERVENTIONS, COMPARATORS, OUTCOMES, TIMING, AND SETTING)
Element
Include
Exclude
Population ........
• People with disabilities (including: physical; cognitive/intellectual/developmental; sensory; serious psychiatric/mental
illness)
• Adults and children
• Specific populations of interest:
—Age
—Gender
—Race/ethnicity
—Economic status
—LGBTQ+ status
—Geographic location (regional and urban/rural)
—Immigration status
—Incarcerated
—Unhoused
—Language spoken
—Use of a guardian/proxy for healthcare decisions
• Studies that do not include people with disabilities or do not
report outcomes according to disability status
VerDate Sep<11>2014
19:48 Oct 31, 2023
Jkt 262001
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
E:\FR\FM\01NON1.SGM
01NON1
74998
Federal Register / Vol. 88, No. 210 / Wednesday, November 1, 2023 / Notices
PICOTS (POPULATIONS, INTERVENTIONS, COMPARATORS, OUTCOMES, TIMING, AND SETTING)—Continued
Element
Include
Exclude
Intervention .......
• Interventions to mitigate barriers and/or improve the receipt
of clinical preventive services among people with disabilities (e.g., modification in policies, practices, and procedures; effective communication; the physical accessibility of
facilities; educational/training programs for healthcare providers)
• Characteristics/components of interventions (KQ3) may include elements such as: staffing, funding, facilities, equipment, training
• Clinical preventive services listed in Appendix B, derived
from USPSTF
Grade A and Grade B recommendations:
—Screening (anxiety disorders, breast cancer, cervical cancer, colorectal cancer, depression, HIV infection, hypertension, intimate partner violence, osteoporosis, diabetes,
unhealth drug or alcohol use)
—Interventions or behavioral counseling (breastfeeding,
falls prevention, perinatal depression, tobacco use/cessation, weight loss, healthy diet and physical activity,
sexually transmitted infections)
• Another intervention
• No intervention
• Receipt of clinical preventive service
• Quality of receipt of clinical preventive service
• Health outcomes related to clinical preventive service
• Patient satisfaction
• Patient well-being
• Harms of the intervention program
• All
• Primary care outpatient clinics
• Community health clinics
• Settings referable from primary care settings
• Emergency departments
• Other settings (e.g., home, residence, mobile care units)
• United States or countries with a ‘‘very high’’ United Nations Human Development Index
• Interventions that do not address barriers to receipt of clinical preventive services for people with disabilities
Comparator ......
Outcome ...........
Timing ...............
Setting ..............
• Preventive services not listed in Appendix B
• Cost-effectiveness
• Outcomes not related to included clinical preventive services listed in Appendix B
Abbreviations: HIV = Human Immunodeficiency Virus; KQ = Key Question; LGBTQ+ = Lesbian Gay Bisexual Transgender Queer/questioning
plus/others; USPSTF = United States Preventive Services Task Force.
Dated: October 26, 2023.
Marquita Cullom,
Associate Director.
Defense Manpower Data Center for
‘‘Verification of Eligibility for Minimum
Essential Coverage Under the Patient
Protection and Affordable Care Act
through a Department of Defense Health
Benefits Plan.’’
[FR Doc. 2023–24057 Filed 10–31–23; 8:45 am]
BILLING CODE 4160–90–P
Centers for Medicare & Medicaid
Services
Privacy Act of 1974; Matching Program
Centers for Medicare &
Medicaid Services (CMS), Department
of Health and Human Services (HHS).
ACTION: Notice of a new matching
program.
ddrumheller on DSK120RN23PROD with NOTICES1
AGENCY:
In accordance with the
Privacy Act of 1974, as amended, the
Department of Health and Human
Services (HHS), Centers for Medicare &
Medicaid Services (CMS) is providing
notice of the re-establishment of a
computer matching program between
CMS and the Department of Defense,
SUMMARY:
VerDate Sep<11>2014
19:48 Oct 31, 2023
Jkt 262001
The deadline for comments on
this notice is December 1, 2023. The reestablished matching program will
commence not sooner than 30 days after
publication of this notice, provided no
comments are received that warrant a
change to this notice. The matching
program will be conducted for an initial
term of 18 months (from approximately
November 30, 2023 to May 29, 2025)
and within 3 months of expiration may
be renewed for up to one additional year
if the parties make no change to the
matching program and certify that the
program has been conducted in
compliance with the matching
agreement.
DATES:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Interested parties may
submit comments on this notice to the
CMS Privacy Act Officer by mail at:
Division of Security, Privacy Policy &
ADDRESSES:
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
Governance, Information Security &
Privacy Group, Office of Information
Technology, Centers for Medicare &
Medicaid Services, Location: N1–14–56,
7500 Security Blvd., Baltimore, MD
21244–1850 or by email at
Barbara.Demopulos@cms.hhs.gov.
If
you have questions about the matching
program, you may contact Anne Pesto,
Senior Advisor, Marketplace Eligibility
and Enrollment Group, Center for
Consumer Information and Insurance
Oversight, Centers for Medicare &
Medicaid Services, at 443–955–9966, by
email at anne.pesto@cms.hhs.gov, or by
mail at 7500 Security Blvd., Baltimore,
MD 21244.
FOR FURTHER INFORMATION CONTACT:
The
Privacy Act of 1974, as amended (5
U.S.C. 552a) provides certain
protections for individuals applying for
and receiving Federal benefits. The law
governs the use of computer matching
by Federal agencies when records in a
system of records (meaning, Federal
agency records about individuals
SUPPLEMENTARY INFORMATION:
E:\FR\FM\01NON1.SGM
01NON1
]]>Agencies
[Federal Register Volume 88, Number 210 (Wednesday, November 1, 2023)]
[Notices]
[Pages 74996-74998]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-24057]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Supplemental Evidence and Data Request on Healthcare Delivery of
Clinical Preventive Services for People With Disabilities
AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.
ACTION: Request for supplemental evidence and data submission.
-----------------------------------------------------------------------
SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) is
seeking scientific information submissions from the public. Scientific
information is being solicited to inform our review on Healthcare
Delivery of Clinical Preventive Services for People with Disabilities,
which is currently being conducted by the AHRQ's Evidence-based
Practice Centers (EPC) Program. Access to published and unpublished
pertinent scientific information will improve the quality of this
review.
DATES: Submission Deadline on or before December 1, 2023.
ADDRESSES:
Email submissions: [email protected].
Print submissions:
Mailing Address: Center for Evidence and Practice Improvement,
Agency for Healthcare Research and Quality, ATTN: EPC SEADs
Coordinator, 5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857.
Shipping Address (FedEx, UPS, etc.): Center for Evidence and
Practice Improvement, Agency for Healthcare Research and Quality, ATTN:
EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville,
MD 20857.
FOR FURTHER INFORMATION CONTACT: Kelly Carper, Telephone: 301-427-1656
or Email: [email protected].
SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and
Quality has commissioned the Evidence-based Practice Centers (EPC)
Program to complete a review of the evidence for Healthcare Delivery of
Clinical Preventive Services for People with Disabilities. AHRQ is
conducting this review pursuant to section 902 of the Public Health
Service Act, 42 U.S.C. 299a.
The EPC Program is dedicated to identifying as many studies as
possible that are relevant to the questions for each of its reviews. In
order to do so, we are supplementing the usual manual and electronic
database searches of the literature by requesting information from the
public (e.g., details of studies conducted). We are looking for studies
that report on Healthcare Delivery of Clinical Preventive Services for
People with Disabilities. The entire research protocol is available
online at: https://effectivehealthcare.ahrq.gov/products/people-with-disabilities/protocol.
This is to notify the public that the EPC Program would find the
following information on Healthcare Delivery of Clinical Preventive
Services for People with Disabilities helpful:
[ssquf] A list of completed studies that your organization has
sponsored for this topic. In the list, please indicate whether results
are available on ClinicalTrials.gov along with the ClinicalTrials.gov
trial number.
[ssquf] For completed studies that do not have results on
ClinicalTrials.gov, a
[[Page 74997]]
summary, including the following elements, if relevant: study number,
study period, design, methodology, indication and diagnosis, proper use
instructions, inclusion and exclusion criteria, primary and secondary
outcomes, baseline characteristics, number of patients screened/
eligible/enrolled/lost to follow-up/withdrawn/analyzed, effectiveness/
efficacy, and safety results.
[ssquf] A list of ongoing studies that your organization has
sponsored for this topic. In the list, please provide the
ClinicalTrials.gov trial number or, if the trial is not registered, the
protocol for the study including, if relevant, a study number, the
study period, design, methodology, indication and diagnosis, proper use
instructions, inclusion and exclusion criteria, and primary and
secondary outcomes.
[ssquf] Description of whether the above studies constitute ALL
Phase II and above clinical trials sponsored by your organization for
this topic and an index outlining the relevant information in each
submitted file.
Your contribution is very beneficial to the Program. Materials
submitted must be publicly available or able to be made public.
Materials that are considered confidential; marketing materials; study
types not included in the review; or information on topics not included
in the review cannot be used by the EPC Program. This is a voluntary
request for information, and all costs for complying with this request
must be borne by the submitter.
The draft of this review will be posted on AHRQ's EPC Program
website and available for public comment for a period of 4 weeks. If
you would like to be notified when the draft is posted, please sign up
for the email list at: https://www.effectivehealthcare.ahrq.gov/email-updates.
The review will answer the following questions. This information is
provided as background. AHRQ is not requesting that the public provide
answers to these questions.
Key Questions
Key Question 1. What are the primary barriers and facilitators\a\
to the receipt of clinical preventive services among people with
disabilities?
a. How do these barriers/facilitators vary according to preventive
service?
b. How do these barriers/facilitators vary according to type and/or
severity of disability?
c. How do these barriers/facilitators vary according to
characteristics such as: gender, race/ethnicity, economic status,
LGBTQ+ status, or geographic location?
Key Question 2. What is the effectiveness of interventions to
improve the receipt of clinical preventive services among people with
disabilities?
a. How does the effectiveness vary according to preventive service?
b. How does the effectiveness vary according to type and/or
severity of disability?
c. How does the effectiveness vary according to characteristics
such as: gender, race/ethnicity, economic status, LGBTQ+ status, or
geographic location?
Key Question 3. What are the characteristics and/or components of
interventions that contribute to their effectiveness (or lack of
effectiveness) in mitigating barriers to the receipt of clinical
preventive services among people with disabilities?
a. How does the effectiveness vary according to preventive service?
b. How does the effectiveness vary according to type and/or
severity of disability?
c. How does the effectiveness vary according to characteristics
such as: gender, race/ethnicity, economic status, LGBTQ+ status, or
geographic location?
Key Question 4. What are the harms of intervention programs to
mitigate barriers to the receipt of clinical preventive services among
people with disabilities?
a. How do the harms vary according to preventive service?
b. How do the harms vary according to type and/or severity of
disability?
c. How do the harms vary according to characteristics such as:
gender, race/ethnicity, economic status, LGBTQ+ status, or geographic
location?
\a\ Categories of barriers and facilitators may include but are not
limited to:
Environment-level (e.g., transportation; need/availability
of guardian or caregiver)
Person-level (e.g., fear; discomfort; functional ability;
self-efficacy)
Provider-level (e.g., disability knowledge/assumptions;
bias or ``ableism''; communication skills)
Health system (e.g., insurance; patient functionality
information in records; procedural accommodations, such as visit length
and clinician reimbursement)
Accessibility of health facilities (e.g., physical
facility; equipment; sensory environment; telehealth)
Accessible communication (e.g., within facility; from
outside of facility)
Policy-level (e.g., Federal or State laws)
PICOTS (Populations, Interventions, Comparators, Outcomes, Timing, and
Setting)
------------------------------------------------------------------------
Element Include Exclude
------------------------------------------------------------------------
Population.................. People with Studies
disabilities that do not include
(including: people with
physical; cognitive/ disabilities or do
intellectual/ not report outcomes
developmental; according to
sensory; serious disability status
psychiatric/mental
illness)
Adults and
children
Specific
populations of
interest:
--Age
--Gender
--Race/ethnicity
--Economic status
--LGBTQ+ status
--Geographic
location (regional
and urban/rural)
--Immigration status
--Incarcerated
--Unhoused
--Language spoken
--Use of a guardian/
proxy for
healthcare
decisions
[[Page 74998]]
Intervention................
Interventions to Interventions that
mitigate barriers do not address
and/or improve the barriers to receipt
receipt of clinical of clinical
preventive services preventive services
among people with for people with
disabilities (e.g., disabilities
modification in
policies,
practices, and
procedures;
effective
communication; the
physical
accessibility of
facilities;
educational/
training programs
for healthcare
providers)
Preventive
Characteristics/ services not listed
components of in Appendix B
interventions (KQ3)
may include
elements such as:
staffing, funding,
facilities,
equipment, training
Clinical ....................
preventive services
listed in Appendix
B, derived from
USPSTF
Grade A and Grade B ....................
recommendations:
--Screening (anxiety
disorders, breast
cancer, cervical
cancer, colorectal
cancer, depression,
HIV infection,
hypertension,
intimate partner
violence,
osteoporosis,
diabetes, unhealth
drug or alcohol
use).
--Interventions or ....................
behavioral
counseling
(breastfeeding,
falls prevention,
perinatal
depression, tobacco
use/cessation,
weight loss,
healthy diet and
physical activity,
sexually
transmitted
infections)
Comparator.................. Another ....................
intervention
No ....................
intervention
Outcome..................... Receipt of Cost-
clinical preventive effectiveness
service
Quality of Outcomes
receipt of clinical not related to
preventive service included clinical
Health preventive services
outcomes related to listed in Appendix
clinical preventive B
service.
Patient ....................
satisfaction
Patient ....................
well-being
Harms of ....................
the intervention
program
Timing...................... All ....................
Setting..................... Primary ....................
care outpatient
clinics
Community ....................
health clinics
Settings ....................
referable from
primary care
settings
Emergency ....................
departments
Other ....................
settings (e.g.,
home, residence,
mobile care units)
United ....................
States or countries
with a ``very
high'' United
Nations Human
Development Index
------------------------------------------------------------------------
Abbreviations: HIV = Human Immunodeficiency Virus; KQ = Key Question;
LGBTQ+ = Lesbian Gay Bisexual Transgender Queer/questioning plus/
others; USPSTF = United States Preventive Services Task Force.
Dated: October 26, 2023.
Marquita Cullom,
Associate Director.
[FR Doc. 2023-24057 Filed 10-31-23; 8:45 am]
BILLING CODE 4160-90-P
